Vitamin D And Chemotherapy Of Colon Cancer.
Higher vitamin D levels in patients with advanced colon cancer appear to benefit reply to chemotherapy and targeted anti-cancer drugs, researchers say. "We found that patients who had vitamin D levels at the highest department had improved survival and improved progression-free survival, compared with patients in the lowest category," said superintend inventor Dr Kimmie Ng, an assistant professor of medicine at Harvard Medical School in Boston. Those patients survived one-third longer than patients with ribald levels of vitamin D - an norm 32,6 months, compared with 24,5 months, the researchers found.
The report, scheduled for spectacle this week at the Gastrointestinal Cancers Symposium in San Francisco, adds more burden to suspicions that vitamin D might be a valuable cancer-fighting supplement. However, colon cancer patients shouldn't analyse to boost vitamin D levels beyond the usual range, one expert said. The study only found an association between vitamin D levels and colon cancer survival rates. It did not examine cause and effect.
Researchers for years have investigated vitamin D as a passive anti-cancer tool, but none of the findings have been strong enough to warrant a recommendation, said Dr Len Lichtenfeld, emissary chief medical officer for the American Cancer Society. "Everyone comes to the same conclusion - yes, there may be some benefit, but we at bottom need to study it carefully so we can be certain there aren't other factors that mutate vitamin D look better than it is.
These findings are interesting, and show that vitamin D may have a lines in improving outcomes in cancer care". In this study, researchers measured blood levels of vitamin D in 1,043 patients enrolled in a appearance 3 clinical attempt comparing three first-line treatments for newly diagnosed, advanced colon cancer. All of the treatments implicated chemotherapy combined with the targeted anti-cancer drugs bevacizumab and/or cetuximab.
Vitamin D is called the "sunshine vitamin" because kind-hearted bodies produce it when the sun's ultraviolet rays whip the skin. It promotes the intestines' ability to absorb calcium and other important minerals, and is fundamental for maintaining strong, healthy bones, according to the US National Institutes of Health. But vitamin D also influences cellular occupation in ways that could be beneficial in treating cancer.
Showing posts with label cancer. Show all posts
Showing posts with label cancer. Show all posts
Wednesday 3 July 2019
Saturday 29 June 2019
Risk Factors For Cancer
Risk Factors For Cancer.
Although about one-third of cancers can be linked to environmental factors or inherited genes, redone inquiry suggests the remaining two-thirds may be caused by unpremeditated mutations. These mutations take place when stem cells divide, according to the study by researchers at Johns Hopkins Kimmel Cancer Center. Stem cells regenerate and substitute for cells that suffer death off. If stem cells make random mistakes and mutate during this stall division, cancer can develop. The more of these mistakes that happen, the greater a person's risk that cells will evolve out of control and develop into cancer, the study authors explained in a Hopkins news release.
Although harmful lifestyle choices, such as smoking, are a contributing factor, the researchers concluded that the "bad luck" of aleatory mutations plays a key role in the development of many forms of cancer. "All cancers are caused by a mix of bad luck, the environment and heredity, and we've created a model that may assistant quantify how much of these three factors contribute to cancer development," said Dr Bert Vogelstein, professor of oncology at the Johns Hopkins University School of Medicine. "Cancer-free longevity in forebears exposed to cancer-causing agents, such as tobacco, is often attributed to their 'good genes,' but the reality is that most of them simply had penetrating luck," added Vogelstein, who is also co-director of the Ludwig Center at Johns Hopkins and an investigator at the Howard Hughes Medical Institute.
The researchers said their findings might not only change-over the way people make out their risk for cancer, but also funding for cancer research. Cristian Tomasetti is a biomathematician and assistant professor of oncology at the Johns Hopkins University School of Medicine and Bloomberg School of Public Health. "If two-thirds of cancer amount across tissues is explained by indefinite DNA mutations that turn up when stem cells divide, then changing our lifestyle and habits will be a huge help in preventing trustworthy cancers, but this may not be as effective for a variety of others," Tomasetti said in the news release.
Although about one-third of cancers can be linked to environmental factors or inherited genes, redone inquiry suggests the remaining two-thirds may be caused by unpremeditated mutations. These mutations take place when stem cells divide, according to the study by researchers at Johns Hopkins Kimmel Cancer Center. Stem cells regenerate and substitute for cells that suffer death off. If stem cells make random mistakes and mutate during this stall division, cancer can develop. The more of these mistakes that happen, the greater a person's risk that cells will evolve out of control and develop into cancer, the study authors explained in a Hopkins news release.
Although harmful lifestyle choices, such as smoking, are a contributing factor, the researchers concluded that the "bad luck" of aleatory mutations plays a key role in the development of many forms of cancer. "All cancers are caused by a mix of bad luck, the environment and heredity, and we've created a model that may assistant quantify how much of these three factors contribute to cancer development," said Dr Bert Vogelstein, professor of oncology at the Johns Hopkins University School of Medicine. "Cancer-free longevity in forebears exposed to cancer-causing agents, such as tobacco, is often attributed to their 'good genes,' but the reality is that most of them simply had penetrating luck," added Vogelstein, who is also co-director of the Ludwig Center at Johns Hopkins and an investigator at the Howard Hughes Medical Institute.
The researchers said their findings might not only change-over the way people make out their risk for cancer, but also funding for cancer research. Cristian Tomasetti is a biomathematician and assistant professor of oncology at the Johns Hopkins University School of Medicine and Bloomberg School of Public Health. "If two-thirds of cancer amount across tissues is explained by indefinite DNA mutations that turn up when stem cells divide, then changing our lifestyle and habits will be a huge help in preventing trustworthy cancers, but this may not be as effective for a variety of others," Tomasetti said in the news release.
New Gene Mutations Linked To Colon Cancer
New Gene Mutations Linked To Colon Cancer.
Researchers who discovered novel gene mutations linked to colon cancer in dark-skinned Americans say their findings could primacy to improved diagnosis and treatment. In the United States, blacks are significantly more likely to result colon cancer and to die from the disease than other racial groups. For the study, the researchers said they employed DNA sequencing to examined 50 million bits of data from 20000 genes. They said that determining gene mutations has been the driving persistence behind all the new drugs created to handle cancer in the last decade.
So "Many of the new cancer drugs on the market today were developed to object specific genes in which mutations were discovered to cause specific cancers," study corresponding initiator Dr Sanford Markowitz, an expert in the genetics of cancer at Case Western Reserve University in Cleveland, said in a university info release. The investigators compared 103 colon cancer samples from unspeakable patients and 129 samples from white patients treated at University Hospitals Case Medical Center in Cleveland.
Researchers who discovered novel gene mutations linked to colon cancer in dark-skinned Americans say their findings could primacy to improved diagnosis and treatment. In the United States, blacks are significantly more likely to result colon cancer and to die from the disease than other racial groups. For the study, the researchers said they employed DNA sequencing to examined 50 million bits of data from 20000 genes. They said that determining gene mutations has been the driving persistence behind all the new drugs created to handle cancer in the last decade.
So "Many of the new cancer drugs on the market today were developed to object specific genes in which mutations were discovered to cause specific cancers," study corresponding initiator Dr Sanford Markowitz, an expert in the genetics of cancer at Case Western Reserve University in Cleveland, said in a university info release. The investigators compared 103 colon cancer samples from unspeakable patients and 129 samples from white patients treated at University Hospitals Case Medical Center in Cleveland.
Wednesday 26 June 2019
How To Use Herbs And Supplements Wisely
How To Use Herbs And Supplements Wisely.
Despite concerns about potentially rickety interactions between cancer treatments and herbs and other supplements, most cancer doctors don't jibber-jabber to their patients about these products, creative research found. Fewer than half of cancer doctors - oncologists - deliver up the subject of herbs or supplements with their patients, the researchers found. Many doctors cited their own scarcity of information as a major reason why they skip that conversation. "Lack of information about herbs and supplements, and awareness of that lack of knowledge is probably one of the reasons why oncologists don't rookie the discussion," said the study's author, Dr Richard Lee, medical kingpin of the Integrative Medicine Program at the University of Texas MD Anderson Cancer Center in Houston.
And "It's at the end of the day about getting more research out there and more education so oncologists can feel comfortable having these conversations". The burn the midnight oil was published recently in the Journal of Clinical Oncology. People with cancer often bring over to herbs and other dietary supplements in an attempt to improve their health and cope with their symptoms, according to background dirt in the study. Although herbs and supplements are often viewed as "natural," they contain active ingredients that might cause deleterious interactions with standard cancer treatments.
Some supplements can cause skin reactions when taken by patients receiving dispersal treatment, according to the American Cancer Society (ACS). Herbs and supplements can also affect how chemotherapy drugs are lost and metabolized by the body, according to the ACS. St John's wort, Panax ginseng and environmental tea supplements are among those that can produce potentially dangerous interactions with chemotherapy, according to the study. For the in the know survey, the researchers asked almost 400 oncologists about their views and knowledge of supplements.
The general age of those who responded was 48 years. About three-quarters of them were men, and about three-quarters were white, the meditate on noted. The specialists polled talked about supplements with 41 percent of their patients. However, doctors initiated only 26 percent of these discussions, the researchers found. The look into also revealed that two out of three oncologists believed they didn't have enough poop about herbs and supplements to response their patients' questions.
Despite concerns about potentially rickety interactions between cancer treatments and herbs and other supplements, most cancer doctors don't jibber-jabber to their patients about these products, creative research found. Fewer than half of cancer doctors - oncologists - deliver up the subject of herbs or supplements with their patients, the researchers found. Many doctors cited their own scarcity of information as a major reason why they skip that conversation. "Lack of information about herbs and supplements, and awareness of that lack of knowledge is probably one of the reasons why oncologists don't rookie the discussion," said the study's author, Dr Richard Lee, medical kingpin of the Integrative Medicine Program at the University of Texas MD Anderson Cancer Center in Houston.
And "It's at the end of the day about getting more research out there and more education so oncologists can feel comfortable having these conversations". The burn the midnight oil was published recently in the Journal of Clinical Oncology. People with cancer often bring over to herbs and other dietary supplements in an attempt to improve their health and cope with their symptoms, according to background dirt in the study. Although herbs and supplements are often viewed as "natural," they contain active ingredients that might cause deleterious interactions with standard cancer treatments.
Some supplements can cause skin reactions when taken by patients receiving dispersal treatment, according to the American Cancer Society (ACS). Herbs and supplements can also affect how chemotherapy drugs are lost and metabolized by the body, according to the ACS. St John's wort, Panax ginseng and environmental tea supplements are among those that can produce potentially dangerous interactions with chemotherapy, according to the study. For the in the know survey, the researchers asked almost 400 oncologists about their views and knowledge of supplements.
The general age of those who responded was 48 years. About three-quarters of them were men, and about three-quarters were white, the meditate on noted. The specialists polled talked about supplements with 41 percent of their patients. However, doctors initiated only 26 percent of these discussions, the researchers found. The look into also revealed that two out of three oncologists believed they didn't have enough poop about herbs and supplements to response their patients' questions.
Monday 17 June 2019
The Animal-Assisted Therapy
The Animal-Assisted Therapy.
People undergoing chemotherapy and emission for cancer may get an poignant lift from man's best friend, a new study suggests. The study, of patients with paramount and neck cancers, is among the first to scientifically test the effects of therapy dogs - trained and certified pooches brought in to effortlessness human anxiety, whether it's from trauma, maltreatment or illness. To dog lovers, it may be a no-brainer that canine companions bring comfort. And cure dogs are already a fixture in some US hospitals, as well as nursing homes, social service agencies, and other settings where rank and file are in need.
Dogs offer something that even the best-intentioned human caregiver can't very much match, said Rachel McPherson, executive director of the New York City-based Good Dog Foundation. "They give unconditional love," said McPherson, whose organizing trains and certifies treatment dogs for more than 350 facilities in New York, New Jersey, Connecticut and Massachusetts. "Dogs don't referee you, or try to give you advice, or tell you their stories," she pointed out.
Instead analysis dogs offer simple comfort to people facing scary circumstances, such as cancer treatment. But while that sounds good, doctors and hospitals on the side of scientific evidence. "We can weather for granted that supportive care for cancer patients, like a healthy diet, has benefits," said Dr Stewart Fleishman, the bring on researcher on the new study. "We wanted to as a matter of fact test animal-assisted therapy and quantify the effects". Fleishman, now retired, was founding governor of cancer supportive services at Beth Israel Medical Center in New York City - now called Mount Sinai Beth Israel.
For the novel study, his team followed 42 patients at the nursing home who were undergoing six weeks of chemotherapy and radiation for head and neck cancers, mostly affecting the bombast and throat. All of the patients agreed to have visits with a therapy dog honest before each of their treatment sessions. The dogs, trained by the Good Dog Foundation, were brought in to the waiting room, or convalescent home room, so patients could spend about 15 minutes with them.
People undergoing chemotherapy and emission for cancer may get an poignant lift from man's best friend, a new study suggests. The study, of patients with paramount and neck cancers, is among the first to scientifically test the effects of therapy dogs - trained and certified pooches brought in to effortlessness human anxiety, whether it's from trauma, maltreatment or illness. To dog lovers, it may be a no-brainer that canine companions bring comfort. And cure dogs are already a fixture in some US hospitals, as well as nursing homes, social service agencies, and other settings where rank and file are in need.
Dogs offer something that even the best-intentioned human caregiver can't very much match, said Rachel McPherson, executive director of the New York City-based Good Dog Foundation. "They give unconditional love," said McPherson, whose organizing trains and certifies treatment dogs for more than 350 facilities in New York, New Jersey, Connecticut and Massachusetts. "Dogs don't referee you, or try to give you advice, or tell you their stories," she pointed out.
Instead analysis dogs offer simple comfort to people facing scary circumstances, such as cancer treatment. But while that sounds good, doctors and hospitals on the side of scientific evidence. "We can weather for granted that supportive care for cancer patients, like a healthy diet, has benefits," said Dr Stewart Fleishman, the bring on researcher on the new study. "We wanted to as a matter of fact test animal-assisted therapy and quantify the effects". Fleishman, now retired, was founding governor of cancer supportive services at Beth Israel Medical Center in New York City - now called Mount Sinai Beth Israel.
For the novel study, his team followed 42 patients at the nursing home who were undergoing six weeks of chemotherapy and radiation for head and neck cancers, mostly affecting the bombast and throat. All of the patients agreed to have visits with a therapy dog honest before each of their treatment sessions. The dogs, trained by the Good Dog Foundation, were brought in to the waiting room, or convalescent home room, so patients could spend about 15 minutes with them.
Human Papillomavirus And Risk For Head And Neck Cancer
Human Papillomavirus And Risk For Head And Neck Cancer.
One paradigm of word-of-mouth HPV (human papillomavirus) infection, HPV16, seems to go the distance a year or longer in men over the age of 45 than it does in younger men, new research indicates. HPV16 is the shape of HPV often associated with the onset of head and neck cancers (oropharyngeal), the contemplate team noted. "Oral HPV16 is the HPV type most commonly found in HPV-driven oropharyngeal cancers, which have been increasing in rate recently in the United States," said study author Christine Pierce Campbell in a American Association for Cancer Research statement release.
She is an assistant member in the activity of Cancer Epidemiology and Center for Infection Research in Cancer at the Moffitt Cancer Center in Tampa, Fla "We don't positive how long oral HPV infection must persist to rise risk for head and neck cancer but we assume it would be similar to cervical infection, where it is generally believed that infections persisting beyond two years greatly burgeon the risk of developing cervical cancer".
One paradigm of word-of-mouth HPV (human papillomavirus) infection, HPV16, seems to go the distance a year or longer in men over the age of 45 than it does in younger men, new research indicates. HPV16 is the shape of HPV often associated with the onset of head and neck cancers (oropharyngeal), the contemplate team noted. "Oral HPV16 is the HPV type most commonly found in HPV-driven oropharyngeal cancers, which have been increasing in rate recently in the United States," said study author Christine Pierce Campbell in a American Association for Cancer Research statement release.
She is an assistant member in the activity of Cancer Epidemiology and Center for Infection Research in Cancer at the Moffitt Cancer Center in Tampa, Fla "We don't positive how long oral HPV infection must persist to rise risk for head and neck cancer but we assume it would be similar to cervical infection, where it is generally believed that infections persisting beyond two years greatly burgeon the risk of developing cervical cancer".
Saturday 15 June 2019
The Basic Knowledge About Breast Cancer
The Basic Knowledge About Breast Cancer.
Many women with bosom cancer shortage basic knowledge about their disease, such as their cancer stage and other characteristics, according to a new study. The deficiency of knowledge was even more pronounced among minority women, the study authors found. This declaration is worrisome because knowing about a health condition can help people understand why therapy is important to follow, experts say. "We certainly were surprised at the number of women who knew very bit about their disease," said Dr Rachel Freedman, assistant professor of medicine at Harvard Medical School and a medical oncologist specializing in bust cancer at the Dana-Farber Cancer Institute.
Although the library didn't specifically look at the reasons behind the lack of knowledge, Freedman suspects that women may be overwhelmed when they're initially diagnosed. In reckoning individual doctors vary in how much gen they give and how well they explain the cancer characteristics. The study is published online Jan 26, 2015 in Cancer. Kimlin Tam Ashing, a professor at the Beckman Research Institute at the City of Hope Cancer Center in Duarte, California, reviewed the study's findings, and said that nimble appointments may also be to point to for the adeptness gap.
In the survey, Freedman and her team asked 500 women four questions about their cancer including questions about tumor stage, grade, and hormone receptor status. Overall, 32 percent to 82 percent of women reported that they knew the answers to these questions. But only 20 percent to 58 percent were truly correct, depending on the characteristics, the investigators found. Just 10 percent of pale women and 6 percent of nefarious and Hispanic women knew all of their cancer characteristics correctly, according to the study.
Cancer "stage" describes the immensity of the cancer, whether it is invasive or not and if lymph nodes are confusing (stages 0 through IV). Two-thirds of ivory women and about half of coal-black and Hispanic women were able to correctly identify their cancer's stage, the researchers found. Cancer "grade" describes how the cancer cells glance under the microscope and can help predict its aggressiveness. Just 24 percent of snow-white women, 15 percent of black women and 19 percent of Hispanic women knew what their cancer year was, according to the study.
Many women with bosom cancer shortage basic knowledge about their disease, such as their cancer stage and other characteristics, according to a new study. The deficiency of knowledge was even more pronounced among minority women, the study authors found. This declaration is worrisome because knowing about a health condition can help people understand why therapy is important to follow, experts say. "We certainly were surprised at the number of women who knew very bit about their disease," said Dr Rachel Freedman, assistant professor of medicine at Harvard Medical School and a medical oncologist specializing in bust cancer at the Dana-Farber Cancer Institute.
Although the library didn't specifically look at the reasons behind the lack of knowledge, Freedman suspects that women may be overwhelmed when they're initially diagnosed. In reckoning individual doctors vary in how much gen they give and how well they explain the cancer characteristics. The study is published online Jan 26, 2015 in Cancer. Kimlin Tam Ashing, a professor at the Beckman Research Institute at the City of Hope Cancer Center in Duarte, California, reviewed the study's findings, and said that nimble appointments may also be to point to for the adeptness gap.
In the survey, Freedman and her team asked 500 women four questions about their cancer including questions about tumor stage, grade, and hormone receptor status. Overall, 32 percent to 82 percent of women reported that they knew the answers to these questions. But only 20 percent to 58 percent were truly correct, depending on the characteristics, the investigators found. Just 10 percent of pale women and 6 percent of nefarious and Hispanic women knew all of their cancer characteristics correctly, according to the study.
Cancer "stage" describes the immensity of the cancer, whether it is invasive or not and if lymph nodes are confusing (stages 0 through IV). Two-thirds of ivory women and about half of coal-black and Hispanic women were able to correctly identify their cancer's stage, the researchers found. Cancer "grade" describes how the cancer cells glance under the microscope and can help predict its aggressiveness. Just 24 percent of snow-white women, 15 percent of black women and 19 percent of Hispanic women knew what their cancer year was, according to the study.
A New Prostate Cancers Treatment Strategy
A New Prostate Cancers Treatment Strategy.
Conventional prudence has it that pongy levels of testosterone help prostate cancers grow. However, a new, small swatting suggests that a treatment strategy called bipolar androgen therapy - where patients alternative between low and high levels of testosterone - might make prostate tumors more responsive to labarum hormonal therapy. As the researchers explained, the primary treatment for advanced prostate cancer is hormonal therapy, which lowers levels of testosterone to stop the tumor from growing. But there's a problem: Prostate cancer cells inevitably worst the therapy by increasing their ability to suck up any unused testosterone in the body.
The new strategy forces the tumor to respond again to higher testosterone levels, portion to reverse its resistance to standard therapy, the researchers say. If confirmed in several ceaseless larger trials, "this could lead to a new treatment approach" for prostate cancers that have grown unaffected to hormonal therapy, said lead researcher Dr Michael Schweizer, an aid professor of oncology at the University of Washington School of Medicine in Seattle.
So "It needs to be stressed that bipolar androgen treatment is not ready for adoption into routine clinical practice, since these studies have not been completed. The backfire was published Jan 7, 2015 in the journal Science Translational Medicine. For the study, 16 men with hormone therapy-resistant prostate cancer received bipolar androgen therapy. Of these patients, seven had their cancer go into remission. In four men, tumors shrank, and in one man, tumors disappeared completely, the researchers report.
Conventional prudence has it that pongy levels of testosterone help prostate cancers grow. However, a new, small swatting suggests that a treatment strategy called bipolar androgen therapy - where patients alternative between low and high levels of testosterone - might make prostate tumors more responsive to labarum hormonal therapy. As the researchers explained, the primary treatment for advanced prostate cancer is hormonal therapy, which lowers levels of testosterone to stop the tumor from growing. But there's a problem: Prostate cancer cells inevitably worst the therapy by increasing their ability to suck up any unused testosterone in the body.
The new strategy forces the tumor to respond again to higher testosterone levels, portion to reverse its resistance to standard therapy, the researchers say. If confirmed in several ceaseless larger trials, "this could lead to a new treatment approach" for prostate cancers that have grown unaffected to hormonal therapy, said lead researcher Dr Michael Schweizer, an aid professor of oncology at the University of Washington School of Medicine in Seattle.
So "It needs to be stressed that bipolar androgen treatment is not ready for adoption into routine clinical practice, since these studies have not been completed. The backfire was published Jan 7, 2015 in the journal Science Translational Medicine. For the study, 16 men with hormone therapy-resistant prostate cancer received bipolar androgen therapy. Of these patients, seven had their cancer go into remission. In four men, tumors shrank, and in one man, tumors disappeared completely, the researchers report.
Friday 14 June 2019
Lung Cancer Prevention In The Mountains
Lung Cancer Prevention In The Mountains.
Americans who explosive in the mountains seem to have stoop rates of lung cancer than those closer to the beach - a pattern that suggests a task for oxygen intake, researchers speculate. Their study of counties across the Western United States found that as cultivation increased, lung cancer rates declined. For every 3300-foot be generated in elevation, lung cancer incidence fell by more than seven cases per 100000 people, researchers reported Jan 13, 2015 in the online annual PeerJ. No one is saying ancestors should head to the mountains to avoid lung cancer - or that those who already live there are in the clear. "This doesn't modest that if you live in Denver, you can go ahead and smoke," said Dr Norman Edelman, elder medical advisor to the American Lung Association.
It's not even certain that elevation, per se, is the insight for the differing lung cancer rates who was not involved in the research. "But this is a really provocative study. It gives us useful information for further research". Kamen Simeonov, one of the researchers on the study, agreed. "Should and Harry move to a higher elevation? No. I wouldn't make any verve decisions based on this". But the findings do support the theory that inhaled oxygen could have a capacity in lung cancer a medical and doctoral student at the University of Pennsylvania in Philadelphia.
As elevation increases, tell pressure dips, which means people inhale less oxygen. And while oxygen is obviously dynamic to life, the body's metabolism of oxygen can have some unwanted byproducts - namely, reactive oxygen species. Over time, those substances can harm body cells and contribute to disease, including cancer. Some late research on lab mice has found that lowering the animals' exposure to oxygen can dally tumor development.
Americans who explosive in the mountains seem to have stoop rates of lung cancer than those closer to the beach - a pattern that suggests a task for oxygen intake, researchers speculate. Their study of counties across the Western United States found that as cultivation increased, lung cancer rates declined. For every 3300-foot be generated in elevation, lung cancer incidence fell by more than seven cases per 100000 people, researchers reported Jan 13, 2015 in the online annual PeerJ. No one is saying ancestors should head to the mountains to avoid lung cancer - or that those who already live there are in the clear. "This doesn't modest that if you live in Denver, you can go ahead and smoke," said Dr Norman Edelman, elder medical advisor to the American Lung Association.
It's not even certain that elevation, per se, is the insight for the differing lung cancer rates who was not involved in the research. "But this is a really provocative study. It gives us useful information for further research". Kamen Simeonov, one of the researchers on the study, agreed. "Should and Harry move to a higher elevation? No. I wouldn't make any verve decisions based on this". But the findings do support the theory that inhaled oxygen could have a capacity in lung cancer a medical and doctoral student at the University of Pennsylvania in Philadelphia.
As elevation increases, tell pressure dips, which means people inhale less oxygen. And while oxygen is obviously dynamic to life, the body's metabolism of oxygen can have some unwanted byproducts - namely, reactive oxygen species. Over time, those substances can harm body cells and contribute to disease, including cancer. Some late research on lab mice has found that lowering the animals' exposure to oxygen can dally tumor development.
Tuesday 11 June 2019
Physical And Mental Health Issues After Cancer Survivors
Physical And Mental Health Issues After Cancer Survivors.
Many US cancer survivors have undetermined palpable and mental health issues long after being cured, a unfamiliar study finds. One expert wasn't surprised. "Many oncologists intuit that their patients may have unmet needs, but suppose that these will diminish with time - the current study challenges that notion," said Dr James Ferrara, moderator of cancer medicine at Tisch Cancer Institute at Mount Sinai in New York City. The revitalized study tangled more than 1500 cancer survivors who completed an American Cancer Society survey asking about unmet needs.
More than one-third trenchant to physical problems related to their cancer or its treatment. For example, incontinence and earthy problems were especially common among prostate cancer survivors, the report found. Cancer dolour often took a toll on financial health, too. About 20 percent of the contemplate respondents said they continued to have problems with paying bills, long after the end of treatment. This was especially genuine for black and Hispanic survivors.
Many respondents also expressed anxiety about the possible return of their cancer, no matter what of the type of cancer or the number of years they had survived, according to the study published online Jan 12, 2015 in the newspaper Cancer. "Overall, we found that cancer survivors are often caught off guard by the remaining problems they experience after cancer treatment," study author Mary Ann Burg, of the University of Central Florida in Orlando, said in a catalogue news release.
Many US cancer survivors have undetermined palpable and mental health issues long after being cured, a unfamiliar study finds. One expert wasn't surprised. "Many oncologists intuit that their patients may have unmet needs, but suppose that these will diminish with time - the current study challenges that notion," said Dr James Ferrara, moderator of cancer medicine at Tisch Cancer Institute at Mount Sinai in New York City. The revitalized study tangled more than 1500 cancer survivors who completed an American Cancer Society survey asking about unmet needs.
More than one-third trenchant to physical problems related to their cancer or its treatment. For example, incontinence and earthy problems were especially common among prostate cancer survivors, the report found. Cancer dolour often took a toll on financial health, too. About 20 percent of the contemplate respondents said they continued to have problems with paying bills, long after the end of treatment. This was especially genuine for black and Hispanic survivors.
Many respondents also expressed anxiety about the possible return of their cancer, no matter what of the type of cancer or the number of years they had survived, according to the study published online Jan 12, 2015 in the newspaper Cancer. "Overall, we found that cancer survivors are often caught off guard by the remaining problems they experience after cancer treatment," study author Mary Ann Burg, of the University of Central Florida in Orlando, said in a catalogue news release.
Friday 7 June 2019
Who Protects Your Children From The Sun More
Who Protects Your Children From The Sun More.
Common learning holds that adults who've wise the trauma of melanoma would go to greater lengths to safeguard their children from the sun's rays. But a new study shows that nearly half of parents who were also melanoma survivors said their descendant had experienced a sunburn over the previous year. "Sunburns were common all the children in our study despite their elevated risk for skin cancer," study author Dr Beth Glenn, an allied professor of health policy and management at the University of California, Los Angeles, said in a university item release.
Sunburn is a major risk for the most deadly type of veneer cancer, and children of survivors are at increased risk for developing the disease as adults. They surveyed 300 fair-skinned and Hispanic melanoma survivors with children aged 17 or younger. The parents were asked about their attitudes nearing melanoma prevention, how they rated their children's risk for the disease, and the Sol protection methods they used for their children.
Common learning holds that adults who've wise the trauma of melanoma would go to greater lengths to safeguard their children from the sun's rays. But a new study shows that nearly half of parents who were also melanoma survivors said their descendant had experienced a sunburn over the previous year. "Sunburns were common all the children in our study despite their elevated risk for skin cancer," study author Dr Beth Glenn, an allied professor of health policy and management at the University of California, Los Angeles, said in a university item release.
Sunburn is a major risk for the most deadly type of veneer cancer, and children of survivors are at increased risk for developing the disease as adults. They surveyed 300 fair-skinned and Hispanic melanoma survivors with children aged 17 or younger. The parents were asked about their attitudes nearing melanoma prevention, how they rated their children's risk for the disease, and the Sol protection methods they used for their children.
Wednesday 5 June 2019
The Overall Rate Of Colon Cancer Has Fallen
The Overall Rate Of Colon Cancer Has Fallen.
Although the overall charge of colon cancer has fallen in just out decades, new research suggests that over the remain 20 years the disease has been increasing among young and early middle-aged American adults. At outgoing are colon cancer rates among men and women between the ages of 20 and 49, a assortment that generally isn't covered by public health guidelines. "This is real," said mug up co-author Jason Zell, an assistant professor in the departments of medicine and epidemiology at the University of California, Irvine. "Multiple explore organizations have shown that colon cancer is rising in those under 50, and our contemplation found the same, particularly among very young adults.
Which means that the epidemiology of this disease is changing, even if the through-and-through risk among young adults is still very low". Results of the study were published recently in the Journal of Adolescent and Young Adult Oncology. The muse about authors noted that more than 90 percent of those with colon cancer are 50 and older. Most Americans (those with no one's own flesh and blood history or heightened endanger profile) are advised to start screening at age 50.
Despite remaining the third most stereotyped cancer in the United States (and the number two cause of cancer deaths), a steady be produced in screening rates has appeared to be the main driving force behind a decades-long plummet in overall colon cancer rates, according to upbringing information in the study. An analysis of US National Cancer Institute data, published survive November in JAMA Surgery, indicated that, as a whole, colon cancer rates had fallen by inartistically 1 percent every year between 1975 and 2010.
But, that review also revealed that during the same time period, the rate among people aged 20 to 34 had in reality gone up by 2 percent annually, while those between 35 and 49 had seen a half-percent yearly uptick. To peruse that trend, the current study focused on data collected by the California Cancer Registry. This registry included dope on nearly 232000 colon cancer cases diagnosed between 1988 and 2009.
Although the overall charge of colon cancer has fallen in just out decades, new research suggests that over the remain 20 years the disease has been increasing among young and early middle-aged American adults. At outgoing are colon cancer rates among men and women between the ages of 20 and 49, a assortment that generally isn't covered by public health guidelines. "This is real," said mug up co-author Jason Zell, an assistant professor in the departments of medicine and epidemiology at the University of California, Irvine. "Multiple explore organizations have shown that colon cancer is rising in those under 50, and our contemplation found the same, particularly among very young adults.
Which means that the epidemiology of this disease is changing, even if the through-and-through risk among young adults is still very low". Results of the study were published recently in the Journal of Adolescent and Young Adult Oncology. The muse about authors noted that more than 90 percent of those with colon cancer are 50 and older. Most Americans (those with no one's own flesh and blood history or heightened endanger profile) are advised to start screening at age 50.
Despite remaining the third most stereotyped cancer in the United States (and the number two cause of cancer deaths), a steady be produced in screening rates has appeared to be the main driving force behind a decades-long plummet in overall colon cancer rates, according to upbringing information in the study. An analysis of US National Cancer Institute data, published survive November in JAMA Surgery, indicated that, as a whole, colon cancer rates had fallen by inartistically 1 percent every year between 1975 and 2010.
But, that review also revealed that during the same time period, the rate among people aged 20 to 34 had in reality gone up by 2 percent annually, while those between 35 and 49 had seen a half-percent yearly uptick. To peruse that trend, the current study focused on data collected by the California Cancer Registry. This registry included dope on nearly 232000 colon cancer cases diagnosed between 1988 and 2009.
Thursday 30 May 2019
The Risk Of Stroke And Aggressive Cancer
The Risk Of Stroke And Aggressive Cancer.
Newly diagnosed cancer patients are at increased jeopardy for rub in the months after they find out they have the disease. And the gamble of stroke is higher among those with more aggressive cancer, a new study says. The findings come from an judgement of Medicare claims submitted between 2001 and 2009 by patients aged 66 and older who had been diagnosed with breast, colorectal, lung, prostate and pancreatic cancer. Compared to cancer-free seniors, those with cancer had a much higher hazard of stroke.
And the danger was highest in the first three months after cancer diagnosis, when the concentration of chemotherapy, radiation and other treatments is typically highest, the researchers at Weill Cornell Medical College in New York City said in a college statement release. The imperil of stroke was highest among patients with lung, pancreatic and colorectal cancers, which are often diagnosed at advanced stages. Stroke peril was lowest among those with breast and prostate cancers, which are often diagnosed when patients have localized tumors, the researchers said.
Newly diagnosed cancer patients are at increased jeopardy for rub in the months after they find out they have the disease. And the gamble of stroke is higher among those with more aggressive cancer, a new study says. The findings come from an judgement of Medicare claims submitted between 2001 and 2009 by patients aged 66 and older who had been diagnosed with breast, colorectal, lung, prostate and pancreatic cancer. Compared to cancer-free seniors, those with cancer had a much higher hazard of stroke.
And the danger was highest in the first three months after cancer diagnosis, when the concentration of chemotherapy, radiation and other treatments is typically highest, the researchers at Weill Cornell Medical College in New York City said in a college statement release. The imperil of stroke was highest among patients with lung, pancreatic and colorectal cancers, which are often diagnosed at advanced stages. Stroke peril was lowest among those with breast and prostate cancers, which are often diagnosed when patients have localized tumors, the researchers said.
Tuesday 28 May 2019
Insulin Levels And Breast Cancer
Insulin Levels And Breast Cancer.
After menopause, in poor insulin levels may vaticinate breast cancer risk even more than excess weight, new research suggests. The restored findings suggest "that it is metabolic health, and not overweight per se, that is associated with increased endanger of breast cancer in postmenopausal women," said study co-author Marc Gunter. He is an collaborator professor of cancer epidemiology and prevention at Imperial College London School of Public Health in England. While momentous insulin levels often occur in overweight or overweight women, some very heavy women have normal levels of the hormone, experts say.
And some normal-weight females have metabolically destructive insulin levels. The study was published Jan. 15 in the log Cancer Research. To assess insulin's role in breast cancer risk, Gunter planned more than 3300 women without diabetes, 497 of whom developed breast cancer over eight years. He analyzed facts on their weight, fasting insulin levels and insulin resistance, in which the body does not reciprocate properly to insulin.
Insulin helps the body use digested food for energy. A body's ineptness to produce insulin or use it properly leads to diabetes. Overweight for the study was defined as a body mass table of contents (BMI) of 25 or more. BMI is a calculation of body fat based on height and weight. "The women who are overweight but who do not have metabolic abnormalities as assessed by insulin defiance are not at increased risk of heart cancer compared to normal-weight women.
On the other hand, normal-weight women with metabolic abnormalities were at approximately the same illustrious risk of breast cancer as overweight women with metabolic abnormalities". Gunter said this outwardly strong link between insulin and breast cancer is not a reason for women to ignore excess pounds. Being overweight or corpulent does increase the chances of developing insulin problems. In his study, strong fasting insulin levels doubled the risk of breast cancer, both for overweight and normal-weight women.
After menopause, in poor insulin levels may vaticinate breast cancer risk even more than excess weight, new research suggests. The restored findings suggest "that it is metabolic health, and not overweight per se, that is associated with increased endanger of breast cancer in postmenopausal women," said study co-author Marc Gunter. He is an collaborator professor of cancer epidemiology and prevention at Imperial College London School of Public Health in England. While momentous insulin levels often occur in overweight or overweight women, some very heavy women have normal levels of the hormone, experts say.
And some normal-weight females have metabolically destructive insulin levels. The study was published Jan. 15 in the log Cancer Research. To assess insulin's role in breast cancer risk, Gunter planned more than 3300 women without diabetes, 497 of whom developed breast cancer over eight years. He analyzed facts on their weight, fasting insulin levels and insulin resistance, in which the body does not reciprocate properly to insulin.
Insulin helps the body use digested food for energy. A body's ineptness to produce insulin or use it properly leads to diabetes. Overweight for the study was defined as a body mass table of contents (BMI) of 25 or more. BMI is a calculation of body fat based on height and weight. "The women who are overweight but who do not have metabolic abnormalities as assessed by insulin defiance are not at increased risk of heart cancer compared to normal-weight women.
On the other hand, normal-weight women with metabolic abnormalities were at approximately the same illustrious risk of breast cancer as overweight women with metabolic abnormalities". Gunter said this outwardly strong link between insulin and breast cancer is not a reason for women to ignore excess pounds. Being overweight or corpulent does increase the chances of developing insulin problems. In his study, strong fasting insulin levels doubled the risk of breast cancer, both for overweight and normal-weight women.
Saturday 25 May 2019
The Risk Of Endometrial Cancer
The Risk Of Endometrial Cancer.
A gathering of health chance factors known as the "metabolic syndrome" may boost older women's risk of endometrial cancer, even if they're not overweight or obese, a unfamiliar study suggests. Metabolic syndrome refers to a put together of health conditions occurring together that increase the risk of heart disease, stroke and diabetes. These conditions embrace high blood pressure, low levels of "good" HDL cholesterol, spaced out levels of triglyceride fats, overweight and obesity, and high fasting blood sugar. "We found that a diagnosis of metabolic syndrome was associated with higher imperil of endometrial cancer, and that metabolic syndrome appeared to development risk regardless of whether the woman was considered obese," Britton Trabert, an investigator in the apportionment of cancer epidemiology and genetics at the US National Cancer Institute, said in an American Association for Cancer Research scuttlebutt release.
The study's design only allowed the investigators to get back an association between metabolic syndrome and endometrial cancer risk. The researchers couldn't check whether or not metabolic syndrome directly causes this cancer of the uterine lining. For the study, the researchers reviewed dirt on more than 16300 American women diagnosed with endometrial cancer between 1993 and 2007. The inquiry authors compared those women to more than 100000 women without endometrial cancer.
A gathering of health chance factors known as the "metabolic syndrome" may boost older women's risk of endometrial cancer, even if they're not overweight or obese, a unfamiliar study suggests. Metabolic syndrome refers to a put together of health conditions occurring together that increase the risk of heart disease, stroke and diabetes. These conditions embrace high blood pressure, low levels of "good" HDL cholesterol, spaced out levels of triglyceride fats, overweight and obesity, and high fasting blood sugar. "We found that a diagnosis of metabolic syndrome was associated with higher imperil of endometrial cancer, and that metabolic syndrome appeared to development risk regardless of whether the woman was considered obese," Britton Trabert, an investigator in the apportionment of cancer epidemiology and genetics at the US National Cancer Institute, said in an American Association for Cancer Research scuttlebutt release.
The study's design only allowed the investigators to get back an association between metabolic syndrome and endometrial cancer risk. The researchers couldn't check whether or not metabolic syndrome directly causes this cancer of the uterine lining. For the study, the researchers reviewed dirt on more than 16300 American women diagnosed with endometrial cancer between 1993 and 2007. The inquiry authors compared those women to more than 100000 women without endometrial cancer.
Tuesday 14 May 2019
Diabetes Medications And Cancer
Diabetes Medications And Cancer.
People with diabetes are less conceivable to take their diabetes medications if they've been diagnosed with cancer, researchers report. The green study included more than 16000 diabetes patients, undistinguished age 68, taking drugs to lower their blood sugar. Of those patients, more than 3200 were diagnosed with cancer. "This review revealed that the medication adherence among users of blood sugar-lowering drugs was influenced by cancer diagnosis," the researchers wrote. "Although the modify of cancer was more pronounced among cancers with a worse prognosis and among those with more advanced cancer stages, the reformation in prognosis associated with these cancers seemed to only partly explain the strike of cancer on medication adherence".
To determine the impact, the Dutch and Canadian researchers analyzed the patients' medication tenure ratio (MPR), which represents the amount of medication patients had in their possession over a unerring period of time. In this study, a 10 percent decline in MPR translated into three days a month where patients did not nick their diabetes medications. At the time of cancer diagnosis, there was an overall 6,3 percent exclude in MPR, followed by a 0,20 percent monthly decline following a cancer diagnosis.
People with diabetes are less conceivable to take their diabetes medications if they've been diagnosed with cancer, researchers report. The green study included more than 16000 diabetes patients, undistinguished age 68, taking drugs to lower their blood sugar. Of those patients, more than 3200 were diagnosed with cancer. "This review revealed that the medication adherence among users of blood sugar-lowering drugs was influenced by cancer diagnosis," the researchers wrote. "Although the modify of cancer was more pronounced among cancers with a worse prognosis and among those with more advanced cancer stages, the reformation in prognosis associated with these cancers seemed to only partly explain the strike of cancer on medication adherence".
To determine the impact, the Dutch and Canadian researchers analyzed the patients' medication tenure ratio (MPR), which represents the amount of medication patients had in their possession over a unerring period of time. In this study, a 10 percent decline in MPR translated into three days a month where patients did not nick their diabetes medications. At the time of cancer diagnosis, there was an overall 6,3 percent exclude in MPR, followed by a 0,20 percent monthly decline following a cancer diagnosis.
Monday 13 May 2019
Complex Diagnostic Of Prostate Cancer
Complex Diagnostic Of Prostate Cancer.
Prostate biopsies that join MRI technology with ultrasound appear to give men better facts regarding the seriousness of their cancer, a new study suggests. The further technology - which uses MRI scans to help doctors biopsy very specified portions of the prostate - diagnosed 30 percent more high-risk cancers than paradigm prostate biopsies in men suspected of prostate cancer, researchers reported. These MRI-targeted biopsies also were better at weeding out low-risk prostate cancers that would not direct to a man's death, diagnosing 17 percent fewer low-grade tumors than classic biopsy, said senior author Dr Peter Pinto.
He is run of the prostate cancer section at the US National Cancer Institute's Center for Cancer Research in Bethesda, MD. These results evince that MRI-targeted biopsy is "a better temperament of biopsy that finds the aggressive tumors that need to be treated but also not finding those undersized microscopic low-grade tumors that are not clinically important but lead to overtreatment". Findings from the study are published in the Jan 27, 2015 Journal of the American Medical Association.
Doctors performing a measure biopsy use ultrasound to influence needles into a man's prostate gland, generally taking 12 core samples from preplanned sections. The problem is, this type of biopsy can be inaccurate, said analyse lead author Dr Mohummad Minhaj Siddiqui, an assistant professor of surgery at the University of Maryland School of Medicine and headman of urologic robotic surgery at the University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore.
And "Occasionally you may be nostalgic for the cancer or you may glance the cancer, just get an lip of it, and then you don't know the full extent of the problem". In a targeted biopsy, MRIs of the suspected cancer are fused with real-time ultrasound images, creating a map of the prostate that enables doctors to pinpoint and investigation unbelieving areas. Prostate cancer testing has become pretty controversial in recent years, with medical experts debating whether too many men are being diagnosed and treated for tumors that would not have led to their deaths.
Removal of the prostate gland can cause unworthy side effects, including impotence and incontinence, according to the US National Cancer Institute. But, even if a tumor isn't life-threatening, it can be psychologically laborious not to manage the tumor. To test the effectiveness of MRI-targeted biopsy, researchers examined just over 1000 men who were suspected of prostate cancer because of an freakish blood screening or rectal exam.
Prostate biopsies that join MRI technology with ultrasound appear to give men better facts regarding the seriousness of their cancer, a new study suggests. The further technology - which uses MRI scans to help doctors biopsy very specified portions of the prostate - diagnosed 30 percent more high-risk cancers than paradigm prostate biopsies in men suspected of prostate cancer, researchers reported. These MRI-targeted biopsies also were better at weeding out low-risk prostate cancers that would not direct to a man's death, diagnosing 17 percent fewer low-grade tumors than classic biopsy, said senior author Dr Peter Pinto.
He is run of the prostate cancer section at the US National Cancer Institute's Center for Cancer Research in Bethesda, MD. These results evince that MRI-targeted biopsy is "a better temperament of biopsy that finds the aggressive tumors that need to be treated but also not finding those undersized microscopic low-grade tumors that are not clinically important but lead to overtreatment". Findings from the study are published in the Jan 27, 2015 Journal of the American Medical Association.
Doctors performing a measure biopsy use ultrasound to influence needles into a man's prostate gland, generally taking 12 core samples from preplanned sections. The problem is, this type of biopsy can be inaccurate, said analyse lead author Dr Mohummad Minhaj Siddiqui, an assistant professor of surgery at the University of Maryland School of Medicine and headman of urologic robotic surgery at the University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore.
And "Occasionally you may be nostalgic for the cancer or you may glance the cancer, just get an lip of it, and then you don't know the full extent of the problem". In a targeted biopsy, MRIs of the suspected cancer are fused with real-time ultrasound images, creating a map of the prostate that enables doctors to pinpoint and investigation unbelieving areas. Prostate cancer testing has become pretty controversial in recent years, with medical experts debating whether too many men are being diagnosed and treated for tumors that would not have led to their deaths.
Removal of the prostate gland can cause unworthy side effects, including impotence and incontinence, according to the US National Cancer Institute. But, even if a tumor isn't life-threatening, it can be psychologically laborious not to manage the tumor. To test the effectiveness of MRI-targeted biopsy, researchers examined just over 1000 men who were suspected of prostate cancer because of an freakish blood screening or rectal exam.
Monday 6 May 2019
New Treating HER2-Positive Breast Cancer
New Treating HER2-Positive Breast Cancer.
For some women with primordial soul tumors, lower-dose chemotherapy and the drug Herceptin may help ward off a cancer recurrence, a supplementary study suggests. Experts said the findings, published in the Jan 8, 2015 New England Journal of Medicine, could put up the first standard treatment approach for women in the untimely stages of HER2-positive breast cancer. HER2 is a protein that helps breast cancer cells thicken and spread, and about 15 to 20 percent of breast cancers are HER2-positive, according to the US National Cancer Institute.
Herceptin (trastuzumab) - one of the newer, called "targeted" cancer drugs - inhibits HER2. But while Herceptin is a benchmark treatment for later-stage cancer, it wasn't disengaged whether it helps women with small, stage 1 breast tumors that have not spread to the lymph nodes. Women with those cancers have a extent low risk of recurrence after surgery and radiation - but it's exhilarated enough that doctors often offer chemotherapy and Herceptin as an "adjuvant," or additional, therapy, explained Dr Sara Tolaney, of the Dana-Farber Cancer Institute in Boston.
The challenge, is balancing the potency benefits against the insignificant effects. So for the new study, her team tested a low-intensity chemo regimen - 12 weeks of a isolated drug, called paclitaxel - plus Herceptin for one year. The researchers found that women who received the drugs were much unlikely to see their bust cancer come back over the next three years. Of the 406 study patients, less than 2 percent had a recurrence.
For some women with primordial soul tumors, lower-dose chemotherapy and the drug Herceptin may help ward off a cancer recurrence, a supplementary study suggests. Experts said the findings, published in the Jan 8, 2015 New England Journal of Medicine, could put up the first standard treatment approach for women in the untimely stages of HER2-positive breast cancer. HER2 is a protein that helps breast cancer cells thicken and spread, and about 15 to 20 percent of breast cancers are HER2-positive, according to the US National Cancer Institute.
Herceptin (trastuzumab) - one of the newer, called "targeted" cancer drugs - inhibits HER2. But while Herceptin is a benchmark treatment for later-stage cancer, it wasn't disengaged whether it helps women with small, stage 1 breast tumors that have not spread to the lymph nodes. Women with those cancers have a extent low risk of recurrence after surgery and radiation - but it's exhilarated enough that doctors often offer chemotherapy and Herceptin as an "adjuvant," or additional, therapy, explained Dr Sara Tolaney, of the Dana-Farber Cancer Institute in Boston.
The challenge, is balancing the potency benefits against the insignificant effects. So for the new study, her team tested a low-intensity chemo regimen - 12 weeks of a isolated drug, called paclitaxel - plus Herceptin for one year. The researchers found that women who received the drugs were much unlikely to see their bust cancer come back over the next three years. Of the 406 study patients, less than 2 percent had a recurrence.
Saturday 4 May 2019
Non-Medical Cancer Treatment Methods
Non-Medical Cancer Treatment Methods.
When it comes to easing the standpoint gear of certain breast cancer drugs, acupuncture may work no better than a "sham" version of the technique, a close-fisted trial suggests. Breast cancer drugs known as aromatase inhibitors often cause side slang shit such as muscle and joint pain, as well as hot flashes and other menopause-like symptoms. And in the new study, researchers found that women who received either physical acupuncture or a sham variation saw a similar rehabilitation in those side effects over eight weeks.
And "That suggests that any benefit from the real acupuncture sessions resulted from a placebo effect," said Dr Patricia Ganz, a cancer maestro at the University of California, Los Angeles School of Medicine who was not knotty in the study. The placebo effect, which is seen in curing studies of all kinds, refers to the phenomenon where some people on an inactive "therapy" get better. However, it's trying to know what to make of the current findings, in part because the study was so small who studies quality-of-life issues in cancer patients.
And "I just don't regard you can come to any conclusions. Practitioners of acupuncture place thin needles into specific points in the body to bring about therapeutic effects such as pain relief. According to routine Chinese medicine, acupuncture works by stimulating certain points on the pelt believed to affect the flow of energy, or "qi" (pronounced "chee"), through the body.
The study, published online Dec 23, 2013 in the record Cancer, included 47 women who were on aromatase inhibitors for early-stage boob cancer. Aromatase inhibitors include the drugs anastrozole (Arimidex), letrozole (Femara) and exemestane (Aromasin). They relieve lower the body's level of estrogen, which fuels tumor rise in most women with breast cancer.
Half were randomly assigned to a weekly acupuncture conference for eight weeks; the other half had sham acupuncture sessions, which involved retractable needles. Overall, women in both groups reported an upgrading in certain drug side effects, such as bright flash severity. But there were no clear differences between the two groups. And in an earlier study, the researchers found the same gauge when they focused on the side effect of muscle and joint pain.
When it comes to easing the standpoint gear of certain breast cancer drugs, acupuncture may work no better than a "sham" version of the technique, a close-fisted trial suggests. Breast cancer drugs known as aromatase inhibitors often cause side slang shit such as muscle and joint pain, as well as hot flashes and other menopause-like symptoms. And in the new study, researchers found that women who received either physical acupuncture or a sham variation saw a similar rehabilitation in those side effects over eight weeks.
And "That suggests that any benefit from the real acupuncture sessions resulted from a placebo effect," said Dr Patricia Ganz, a cancer maestro at the University of California, Los Angeles School of Medicine who was not knotty in the study. The placebo effect, which is seen in curing studies of all kinds, refers to the phenomenon where some people on an inactive "therapy" get better. However, it's trying to know what to make of the current findings, in part because the study was so small who studies quality-of-life issues in cancer patients.
And "I just don't regard you can come to any conclusions. Practitioners of acupuncture place thin needles into specific points in the body to bring about therapeutic effects such as pain relief. According to routine Chinese medicine, acupuncture works by stimulating certain points on the pelt believed to affect the flow of energy, or "qi" (pronounced "chee"), through the body.
The study, published online Dec 23, 2013 in the record Cancer, included 47 women who were on aromatase inhibitors for early-stage boob cancer. Aromatase inhibitors include the drugs anastrozole (Arimidex), letrozole (Femara) and exemestane (Aromasin). They relieve lower the body's level of estrogen, which fuels tumor rise in most women with breast cancer.
Half were randomly assigned to a weekly acupuncture conference for eight weeks; the other half had sham acupuncture sessions, which involved retractable needles. Overall, women in both groups reported an upgrading in certain drug side effects, such as bright flash severity. But there were no clear differences between the two groups. And in an earlier study, the researchers found the same gauge when they focused on the side effect of muscle and joint pain.
Flu Vaccination Is Needed For Cancer Patients
Flu Vaccination Is Needed For Cancer Patients.
People with cancer camouflage a higher gamble for serious flu-related complications, so getting vaccinated should be at the top of their to-do liber veritatis this winter, an expert says in Dec 2013. "The flu shot is recommended annually for cancer patients, as it is the most striking way to prevent influenza and its complications," Dr Mollie deShazo, an accomplice professor of medicine in the division of hematology and oncology at the University of Alabama at Birmingham, said in a scuttlebutt release. "The flu vaccine significantly lowers the risk of acquiring the flu.
It is not 100 percent effective, but it is the best gizmo we have". Pneumonia, bronchitis, sinus infections and ear infections are examples of flu-related complications, according to the US Centers for Disease Control and Prevention. It is recommended that anyone who has not done so already get a flu shot. Although this year's flu opportunity is off to a dull start nationally, the add of cases in the south-central United States is rapidly increasing, with five deaths already reported in Texas.
People with cancer camouflage a higher gamble for serious flu-related complications, so getting vaccinated should be at the top of their to-do liber veritatis this winter, an expert says in Dec 2013. "The flu shot is recommended annually for cancer patients, as it is the most striking way to prevent influenza and its complications," Dr Mollie deShazo, an accomplice professor of medicine in the division of hematology and oncology at the University of Alabama at Birmingham, said in a scuttlebutt release. "The flu vaccine significantly lowers the risk of acquiring the flu.
It is not 100 percent effective, but it is the best gizmo we have". Pneumonia, bronchitis, sinus infections and ear infections are examples of flu-related complications, according to the US Centers for Disease Control and Prevention. It is recommended that anyone who has not done so already get a flu shot. Although this year's flu opportunity is off to a dull start nationally, the add of cases in the south-central United States is rapidly increasing, with five deaths already reported in Texas.
Subscribe to:
Posts (Atom)